Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 26, 2011
Woodcliff Lake, NJ, December 26, 2011 - Eisai Inc. announced today that it resubmitted the New Drug Application (NDA) for the investigational AMPA-type glutamate receptor antagonist perampanel for...
-
Dec 15, 2011
Tokyo, Japan, December 15, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...
-
Dec 2, 2011
Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122, a study of its investigational agent farletuzumab (MORAb-003), in platinum-resistant ovarian cancer. This decision was based...
-
Dec 2, 2011Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics
Tokyo, Japan, December 2, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that the company's U.S. research subsidiary H3 Biomedicine...
-
Dec 1, 2011
Tokyo, Japan, December 1, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...